enow.com Web Search

  1. Ad

    related to: castration resistant cancer prognosis

Search results

  1. Results from the WOW.Com Content Network
  2. Prostate cancer - Wikipedia

    en.wikipedia.org/wiki/Prostate_cancer

    Eventually cancer cells can grow resistant to this treatment. This most-advanced stage of the disease, called castration-resistant prostate cancer, is treated with continued hormone therapy alongside the chemotherapy drug docetaxel. Some tumors metastasize (spread) to other areas of the body, particularly the bones and lymph nodes.

  3. DU145 - Wikipedia

    en.wikipedia.org/wiki/DU145

    Castration-resistant prostate cancer (CRPC) is prostate cancer that progresses despite extremely low testosterone in the body often due to medical castration. [4] Unlike many other types of prostate cancer, CRPC do not need normal testosterone levels, but they still require regular androgen receptors (AR).

  4. Cabazitaxel - Wikipedia

    en.wikipedia.org/wiki/Cabazitaxel

    In a phase III trial with 755 men for the treatment of castration-resistant prostate cancer, median survival was 15.1 months for participants receiving cabazitaxel versus 12.7 months for participants receiving mitoxantrone. Cabazitaxel was associated with more grade 3–4 neutropenia (81.7%) than mitoxantrone (58%). [13]

  5. Management of prostate cancer - Wikipedia

    en.wikipedia.org/wiki/Management_of_prostate_cancer

    This combination likely improves overall and cancer-specific survival by slowing the spread of the cancer. However, taxane-based chemotherapy may cause an increase in side effects. [45] Medications that block the production of adrenal androgens such as DHEA include ketoconazole and aminoglutethimide. Because the adrenal glands make only about 5 ...

  6. Tasquinimod - Wikipedia

    en.wikipedia.org/wiki/Tasquinimod

    Tasquinimod has been mostly studied in prostate cancer, but its mechanism of action suggests that it could be used to treat other cancers. Castration-resistant prostate cancer (CRPC), formerly called hormone-resistant or hormone-refractory prostate cancer, is prostate cancer that grows despite medical or surgical androgen deprivation therapy.

  7. Darolutamide - Wikipedia

    en.wikipedia.org/wiki/Darolutamide

    Darolutamide, sold under the brand name Nubeqa, is an antiandrogen medication which is used in the treatment of non-metastatic castration-resistant prostate cancer in men. [8] [4] [5] [9] [10] It is specifically approved to treat non-metastatic castration-resistant prostate cancer (nmCRPC) in conjunction with surgical or medical castration. [4]

  8. Sipuleucel-T - Wikipedia

    en.wikipedia.org/wiki/Sipuleucel-T

    Other names for this stage are metastatic castrate-resistant (mCRPC) and androgen independent (AI) or (AIPC). This stage leads to mCRPC with lymph node involvement and distal (distant) tumors; this is the lethal stage of CaP. The prostate cancer staging designation is T4,N1,M1c. [5] [6] [7]

  9. Enzalutamide - Wikipedia

    en.wikipedia.org/wiki/Enzalutamide

    Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. [2] [9] It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), [2] nonmetastatic castration-resistant prostate cancer, [2] and metastatic castration-sensitive prostate ...

  1. Ad

    related to: castration resistant cancer prognosis